LATEST NEWS

Guilford Street Laboratories launches ImmunoTADA™ for in patient NHS use to support Fabry disease care.

London, UK — May 2026 — Guilford Street Laboratories (GSL) today announced the successful launch of ImmunoTADA™ - a mass spectrometry-based anti-drug antibody test in partnership with the NHS - into in-patient clinical use for patients living with Fa....

The Innovate UK Business Growth Scaleup Programme supports a select group of companies on a journey to exponential growth. Guilford Street Laboratories (GSL) is proud to have been accepted, following a rigorous three-stage screening process. The initiative will help GSL scale up its world leading digital services and technology innovations. The programme is designed to support highly innovative....

Guilford Street Laboratories named Official Tech Climber for 2026 and recognised as 'Most Innovative' Company London, UK - 20/4/26 - Guilford Street Laboratories (GSL) is pleased to announce that it has been named an Official Tech Climber for 2026 as part of the Tech Climbers Liverpool City Region campaign and has also been recognised as the ‘Most Innovative’ Company among this year&r....

Guilford Street Laboratories announces expansion into new laboratory space at Kadans Science Partner, King’s Cross London, UK - 15/4/26 - Guilford Street Laboratories (GSL) today announced a significant expansion of its laboratory infrastructure with the establishment of a new, stateoftheart laboratory space at Kadans Science Partner in King’s Cross, London. This milestone marks an ....

Guilford Street Laboratories (GSL) has successfully completed its third funding round, marking another significant milestone in the company’s growth journey in a deal advised by GS Verde – An AAB Group Company. The round was oversubscribed, reflecting strong investor confidence in GSL’s vision, progress and future potential, with participation from both new and existing investor....

2025 marked a significant milestone for GSL as we broadened our presence to support rapid growth and innovation. To accommodate our expanding team and evolving capabilities, we opened a new office at Central Tech in Liverpool—a hub for cutting- edge science and technology. This strategic move strengthens our ability to collaborate with partners, accelerate clinical development, and deliver n....

A Multiplexed Urinary Biomarker Panel Has Potential for Alzheimer’s Disease Diagnosis Using Targeted Proteomics and Machine Learning

2025 was a landmark year for GSL, driving growth across our business and strengthening the team behind our innovations. We expanded our capabilities and welcomed exceptional new colleagues, each bringing expertise and passion that continue to power our success in precision diagnostics. Their contributions are helping us accelerate clinical development, deliver next-generation solutions, and shape....